# An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001

> **NCT03041909** · PHASE2 · COMPLETED · sponsor: **Global Blood Therapeutics** · enrollment: 5 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** GBT440

## Key facts

- **NCT ID:** NCT03041909
- **Lead sponsor:** Global Blood Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-08
- **Primary completion:** 2017-06
- **Final completion:** 2017-08
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2019-01-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03041909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03041909, "An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT03041909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*